|
|
Blood, 1 November 2007, Vol. 110, No. 9, pp. 3365-3373.
Prepublished online as a Blood First Edition Paper on July 18, 2007; DOI 10.1182/blood-2007-03-079673.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Azim Mohamedali1,
Joop Gäken1,
Natalie A. Twine1,
Wendy Ingram1,
Nigel Westwood1,
Nicholas C. Lea1,
Janet Hayden1,
Nora Donaldson2,
Carlo Aul3,
Norbert Gattermann4,
Aristotle Giagounidis4,
Ulrich Germing4,
Alan F. List5, and
Ghulam J. Mufti1
1 Department of Haematological Medicine, King's College London School of Medicine, London, United Kingdom;
2 Research and Development, King's College Hospital, London, United Kingdom;
3 St Johannes Hospital, Medizinische Klinik II, Duisberg, Germany;
4 Department of Haematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany;
5 H. Lee Moffitt Cancer Center and Research Institute, Department of Hematologic Malignancies, Tampa, FL
Low-risk myelodysplastic syndrome (MDS) with normal cytogenetics accounts for approximately 50% of MDS patients. There are no pathognomonic markers in these cases and the diagnosis rests on cytomorphologic abnormalities in bone marrow and/or peripheral blood. Affymetrix high-resolution single-nucleotide polymorphism (SNP) genotyping microarrays allow detection of cytogenetically cryptic genomic aberrations. We have studied 119 low-risk MDS patients (refractory anemia [RA] = 22; refractory cytopenia with multilineage dysplasia [RCMD] = 51; refractory anemia with ringed sideroblasts [RARS] = 12; refractory cytopenia with multilineage dysplasia with ringed sideroblasts [RCMD-RS] = 12; 5q– syndrome = 16; refractory anemia with excess blasts [RAEB] = 6) using SNP microarrays to seek chromosomal markers undetected by conventional cytogenetics. Loss of heterozygosity (LOH) detected by 50K arrays was verified using 250K and 500K arrays. We demonstrate the presence of uniparental disomy (UPD) in 46%, deletions in 10%, and amplifications in 8% of cases. Copy number (CN) changes were acquired, whereas UPDs were also detected in constitutional DNA. UPD on 4q was identified in 25% of RARS, 12% of RCMD with normal cytogenetics, 17% of RAEB, and 6% of 5q– syndrome cases. Univariate analysis showed deletions (P = .04) and International Prognostic Scoring System (IPSS; P < .001) scores correlated with overall survival; however, on multivariate analysis only IPSS scores retained prognostic significance (P < .001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Tefferi and J. W. Vardiman
Myelodysplastic Syndromes
N. Engl. J. Med.,
November 5, 2009;
361(19):
1872 - 1885.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Tiu, L. P. Gondek, C. L. O'Keefe, J. Huh, M. A. Sekeres, P. Elson, M. A. McDevitt, X. F. Wang, M. J. Levis, J. E. Karp, et al.
New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia
J. Clin. Oncol.,
November 1, 2009;
27(31):
5219 - 5226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, V. Della-Valle, F. Picard, F. Viguie, B. Quesnel, O. Beyne-Rauzy, E. Solary, et al.
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Blood,
October 8, 2009;
114(15):
3285 - 3291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sekeres and D. P. Steensma
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
Blood,
September 24, 2009;
114(13):
2575 - 2580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Mohamedali, A. E. Smith, J. Gaken, N. C. Lea, S. A. Mian, N. B. Westwood, C. Strupp, N. Gattermann, U. Germing, and G. J. Mufti
Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
J. Clin. Oncol.,
August 20, 2009;
27(24):
4002 - 4006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Orazi and M. B. Czader
Myelodysplastic Syndromes
Am J Clin Pathol,
August 1, 2009;
132(2):
290 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Jankowska, H. Szpurka, R. V. Tiu, H. Makishima, M. Afable, J. Huh, C. L. O'Keefe, R. Ganetzky, M. A. McDevitt, and J. P. Maciejewski
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
Blood,
June 18, 2009;
113(25):
6403 - 6410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Delhommeau, S. Dupont, V. D. Valle, C. James, S. Trannoy, A. Masse, O. Kosmider, J.-P. Le Couedic, F. Robert, A. Alberdi, et al.
Mutation in TET2 in Myeloid Cancers
N. Engl. J. Med.,
May 28, 2009;
360(22):
2289 - 2301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
J. Clin. Oncol.,
February 10, 2009;
27(5):
782 - 790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Dunbar, L. P. Gondek, C. L. O'Keefe, H. Makishima, M. S. Rataul, H. Szpurka, M. A. Sekeres, X. F. Wang, M. A. McDevitt, and J. P. Maciejewski
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Cancer Res.,
December 15, 2008;
68(24):
10349 - 10357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Starczynowski, S. Vercauteren, A. Telenius, S. Sung, K. Tohyama, A. Brooks-Wilson, J. J. Spinelli, C. J. Eaves, A. C. Eaves, D. E. Horsman, et al.
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Blood,
October 15, 2008;
112(8):
3412 - 3424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood,
August 15, 2008;
112(4):
965 - 974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, C. Fidler, N. Nadig, A. Giagounidis, M. G. Della Porta, L. Malcovati, S. Killick, N. Gattermann, C. Aul, J. Boultwood, et al.
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
Haematologica,
July 1, 2008;
93(7):
994 - 1000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. P. Gondek, R. Tiu, C. L. O'Keefe, M. A. Sekeres, K. S. Theil, and J. P. Maciejewski
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Blood,
February 1, 2008;
111(3):
1534 - 1542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Nimer
MDS: A Stem Cell Disorder--But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease?
Hematology,
January 1, 2008;
2008(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|